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Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and prostate cancer. Serum levels of oestradiol and 
testosterone are controlled by the hypothalamic–pituitary–gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries and in postmenopausal women 
by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by 
castration. In postmenopausal women selective oestrogen receptor modulators (e.g. tamoxifen) or aromatase inhibitors are used. Hormone therapy can be used to reduce the 
size of the primary cancer prior to radical surgery or radiotherapy or to reduce the risk of recurrence. Hormone therapy is highly effective in patients with locally advanced or 
metastatic disease, with a high response rate. Most patients eventually relapse with ‘castrate-refractory’ disease, for which increasing numbers of active agents are entering 
clinical practice. 
 




This paper will concentrate on the management of breast and prostate cancers in which the impact of hormone therapy is most clinically significant. Increased exposure to 
endogenous or exogenous oestrogens may be linked to the development of breast cancer (Table 1). However, there is no evidence that exposure to androgens is important in 
the development of prostate cancer. 
Historical evidence 
In 1896 Beatson demonstrated that surgical oophorectomy resulted in tumour regression in premenopausal women with metastatic breast cancer. Charles Huggins was 
awarded the Nobel Prize for medicine in 1966 following his discovery that surgical orchidectomy was a successful treatment for metastatic prostate cancer. 
Hormone synthesis 
Oestrogen is synthesized from cholesterol in the parafollicular ovaries in premenopausal women via the hypothalamic–pituitary–gonadal axis (Figure 1), and in the adrenals in 
postmenopausal women. In premenopausal women, oestrogen production is cyclical: gonadotrophin-releasing hormone (GnRH) is released from the hypothalamus with a 
circadian rhythm under direct feedback by circulating hormones. GnRH reacts with anterior pituitary receptors, leading to the release of luteinizing and follicle-stimulating 
hormone; these stimulate the ovaries to produce oestradiol. 
In postmenopausal women, the main site of oestrogen synthesis is adipose tissue. Here, adrenal androgens (e.g. androstenedione) are converted from aromatase to 
oestrone. Oestrone is then converted to oestradiol by 17β-OH dehydrogenase. Postmenopausal synthesis varies depending on environmental and genetic factors (e.g. 
obesity). 
In men, the main circulating androgen is testosterone, 90% of which is produced by the testicular Leydig cells under control of the hypothalamic–pituitary axis, as above. 
The remaining circulating androgens (e.g. dihydroxyandrostenedione) are produced in the adrenal cortex from cholesterol. Testosterone is  metabolized by 5α-
reductase within the prostate to the more biologically active dihydrotestosterone, which acts as the ligand for  the androgen receptor (AR).  
Hormone receptors 
In breast cancer, approximately 80% of postmenopausal women and 50% of premenopausal women have hormone receptor-positive disease. The degree of positivity is 
defined by the level of expression of both oestrogen (ER) and progesterone receptors, which are routinely measured immunohistochemically in newly diagnosed cases. 
Systemic treatment and, to some extent, prognosis is guided by hormone receptor status. 
In contrast, measurement of ARs is not currently routinely performed in prostate cancer – it has no therapeutic or prognostic value because both hormone-dependent 
and ‘castrate-refractory’ prostate cancers (CRPCs) possess functioning ARs. Recent work suggests that AR variants may underlie resistance to castration.1  
Hormone therapy in breast cancer 
Ovarian ablation 
In premenopausal women oestrogen suppression is achieved by chemical ablation, radiation to the ovaries or surgical oophorectomy. Chemical ablation is reversible and 
achieved by using a GnRH agonist (GnRHa or LHRHa) such as goserelin, usually as a monthly depot injection. 
Other hormonal agents in breast cancer  
An increasing number of hormonal treatment options are available to treat breast cancer. A description of the different licensed drugs is given in Table 2. The most commonly 
used treatments include tamoxifen and aromatase inhibitors (AIs). 
 
Tamoxifen: this is a selective oestrogen receptor modulator with complex actions on ERs, acting predominantly as an antagonist, with a weak agonist effects. In ER-positive 
early breast cancer, 5 years of tamoxifen after surgery reduces the annual recurrence rate by 41% and annual mortality rate by 34%.2 There is evidence of a reduction in 
breast cancer recurrence and mortality by continuing tamoxifen in ER-positive disease for 10 years rather than stopping at 5 years.3 
Tamoxifen may be used in premenopausal and postmenopausal women. The main adverse effects are hot flushes, night sweats and vaginal discharge. There is an 
increased risk of thrombotic events. Vaginal bleeding should be promptly evaluated because of the increased risk of endometrial cancer.4 
 
Aromatase inhibitors: several Phase III clinical trials have established third-generation AIs as the new gold standard in the adjuvant hormonal treatment of receptor-positive 
early breast cancer. They are contraindicated in premenopausal women unless ovarian suppression has been induced. There are three main approaches with early breast 
cancer: 
• up-front use for 5 years 
• planned or unplanned switching, i.e. use of AIs for 2–3 years after 2–3 years of tamoxifen 
• extended therapy, i.e. after 5 years’ use of tamoxifen. 
 The main toxicities of AIs are hot flushes, arthralgia, reduced bone mineral density and increased risk of fractures. Women at risk of osteoporosis should be carefully 
monitored or treated with bisphosphonates where necessary.5 
A new approach is the use of AIs in combination with signal transduction or pathway inhibitors. Everolimus is an mTOR inhibitor licensed for use in combination with 
exemestane in the metastatic setting.6 
 
 
Main indications for hormonal therapy in breast cancer 
 
• As a neoadjuvant  to reduce the size of the primary tumour, making it operable or reducing the extent of surgery, for example from mastectomy to wide local excision  
• As an adjuvant after surgery to reduce the risk of recurrence and improve survival 
• As a palliative treatment to shrink and control large inoperable cancers 
• As a palliative treatment for metastatic disease to prolong and improve quality of life. 
Hormone therapy in prostate cancer 
Androgen deprivation therapy (ADT) 
Serum testosterone is reduced to castrate levels by surgical or chemical castration, using LHRHa or the newer LHRH antagonists. Castration can lead to  hot flushes, sweats 
and reduced libido. Patients may notice reduced muscle mass, reduced strength and weight gain. There can be loss of bone mineral density and there are concerns of an 
increased risk of fatal cardiac events. 
Initial use of LHRHa results in a surge in serum testosterone, which may worsen symptoms: all patients should take oral antiandrogens for at least 3 weeks, starting 
1–2 weeks prior to initial LHRHa injection. This is not needed with LHRH antagonists, which are preferred in emergency situations.  
Other hormonal agents in prostate cancer 
The hormonal agents commonly used in the management of CRPC are described in Table 3. 
Bicalutamide is a non-steroidal antiandrogen and competitive AR inhibitor that is often used as the initial agent for CRPC, with a response rate up to 66%. Single-
agent bicalutamide (at a dose of 150 mg daily) can be used as an alternative to ADT in some clinical situations. There is a lower incidence of erectile dysfunction but equivalent 
efficacy has not been proven. 
Degarelix is an LHRH antagonist and does not cause a testosterone flare. It rapidly achieves castrate levels of testosterone and can be used in emergency situations 
such as new diagnoses presenting with cord compression.  
Abiraterone acetate and enzalutamide are newer agents causing much greater AR suppression, through different mechanisms; they have been shown to prolong 
survival both before and after docetaxel chemotherapy.7–10 
Corticosteroids are highly active in CRPC but have no proven survival advantage. Long-term use is associated with typical glucocorticoid adverse effects, such as 
proximal myopathy and reduced bone mineral density, and patients require regular review. 
Main indications for hormonal treatment in prostate cancer 
 
• As a neoadjuvant prior to radiotherapy to improve local and biochemical (prostate-specific antigen) control in patients with locally advanced tumours  
• As an adjuvant following radiotherapy to improve overall survival in high-risk disease  
•Palliatively for metastatic or recurrent prostate cancer. Almost 100% of patients respond, with a median duration of response of 12 months. 
Hormone resistance 
Resistance develops in nearly all patients with metastatic breast and prostate cancer who initially respond to hormone therapy, resulting in disease progression. The molecular 
causes of resistance are complex, varied and not well understood. Mechanisms may include increased sensitivity of hormone receptors, pathway activation without exposure to 
hormones (constitutive activation) or up-regulated downstream survival pathways. As these become better characterized, new agents can be developed and trialled. 
Table 1 
 
Hormonal risks for breast cancer  
Risk factors  Protective factors  
Early menarche Breast-feeding 
Late menopause Young age at full-term pregnancy 
Nulliparity  
Obesity  
Hormone replacement therapy  
 
Table 2 
Hormonal therapies in breast cancer  
Drug Type Dose/route Mode of action 
Tamoxifen Anti-oestrogen 20 mg daily p.o. Competes with oestradiol for ER binding 
Anastrozole Non-steroidal aromatase inhibitor 1 mg daily p.o. Competitive aromatase inhibition 
Letrozole Non-steroidal aromatase inhibitor 2.5 mg daily p.o. Competitive aromatase inhibition 
Exemestane Steroidal aromatase inhibitor 25 mg daily p.o. Irreversible aromatase inhibition 
Fulvestrant Oestrogen receptor antagonist 250 mg monthly i.m. Down-regulation of the ER protein 
Megestrol acetate Progestin 80–160 mg daily p.o. Cellular action not fully understood 
   Down-regulation of ovarian steroidogenesis 
    
 
ER, oestrogen receptor; i.m., intramuscular; p.o., oral. 
Table 3 
Hormonal therapies in prostate cancer  
Drug Type Dose/route Mode of action 
Goserelin LHRH agonist 3.6 mg every 28 days or 10.8 mg every 3 months s.c. Reduced pituitary production of LH and FSH 
Leuprorelin LHRH agonist 3.75 mg every 28 days or 11.25 mg every 3 months – 
s.c./i.m. 
Reduced pituitary production of LH and FSH 
 
Degarelix LHRH antagonist 240 mg then 80 mg every 28 days s.c. Reduced pituitary production of LH and FSH 
Bicalutamide Non-steroidal antiandrogen 50 mg (combination dose) or 150 mg (single agent) daily p.o. Competitive AR inhibition 
Prednisolone Corticosteroid 5–10 mg daily p.o. Adrenal suppression 
Dexamethasone Corticosteroid 0.5–2 mg daily p.o. Adrenal suppression 
Abiraterone acetate Androgen synthesis inhibitor 
1000 mg daily p.o. with prednisolone 5 mg twice daily 
p.o. 
Reduced androgen production within 
adrenal glands and prostate cancer cells 
Enzalutamide AR inhibitor 160 mg daily p.o. Competitive AR inhibition, block of AR translocation to the nucleus 
 
AR, androgen receptor; FSH, follicle-stimulating hormone; i.m., intramuscular; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone; p.o., oral; s.c., subcutaneous. 
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What’s new 
  The mechanisms behind resistance to hormonal therapies are being better characterized  New drugs targeting these mechanisms have shown a survival advantage over previous best care and have entered routine practice  Further agents overcoming resistance to these newer agents are now being studied  In breast cancer, pathway inhibitors are used in combination with aromatase inhibitors to overcome resistance  In prostate cancer these are abiraterone acetate and enzalutamide 
 
 
